CD274 and urothelial carcinoma: We used a dataset of urothelial carcinoma treated with anti-PD-L1 (Imvigor210) (progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR)) and a dataset of non-small cell lung carcinoma patients treated with anti-PD-1/PD-L1 (GSE135222).